Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Related Posts

HP accounts for 47 inferior drugs in March alert

Kullu: In an alert issued for the month of March, the Central Drugs Standard Control Organisation (CDSCO) has declared a total of 141 drugs to be of substandard quality. Out…

Civil society group SAM calls for greater transparency involving clinical trials

The group had approached the Supreme Court, raising concerns on clinical trials in a Public Interest Litigation in 2012 Civil society group Swasthya Adhikar Manch (SAM) has called for greater…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert

Civil society group SAM calls for greater transparency involving clinical trials

Civil society group SAM calls for greater transparency involving clinical trials

Different packaging, typos expose fake Mounjaro racket

Different packaging, typos expose fake Mounjaro racket

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines